| abstract |
The disclosure relates to 9 beta -aryloxy prostane derivatives, for example 16-(3-chlorophenoxy)-11 alpha ,15 alpha -dihydroxy-16-methyl-9 beta -phenoxy-18,19,20-trinor-5-cis,13-trans-prostadienoic acid, which possess high activity as abortifacients, cervical softeners, inducers of parturition or inhibitors of gastric acid production in mammals. These properties are typical of prostaglandin analogues of the E series, but chemically the new 9 beta -aryloxy prostane derivatives are prostaglandin F series analogues and are therefore more stable than the E series analogues previously used for the above purposes. The new derivatives are manufactured by known analogy processes, and are formulated in conventional manner. |